Cargando…
Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients
Advances in DNA sequencing have made genetic testing fast and affordable, but limitations of testing processes are impeding realisation of patient benefits. Ovarian cancer exemplifies the potential value of genetic testing and the shortcomings of current pathways to access testing. Approximately 15%...
Autores principales: | George, Angela, Riddell, Daniel, Seal, Sheila, Talukdar, Sabrina, Mahamdallie, Shazia, Ruark, Elise, Cloke, Victoria, Slade, Ingrid, Kemp, Zoe, Gore, Martin, Strydom, Ann, Banerjee, Susana, Hanson, Helen, Rahman, Nazneen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4942815/ https://www.ncbi.nlm.nih.gov/pubmed/27406733 http://dx.doi.org/10.1038/srep29506 |
Ejemplares similares
-
CSN and CAVA: variant annotation tools for rapid, robust next-generation sequencing analysis in the clinical setting
por: Münz, Márton, et al.
Publicado: (2015) -
The ICR639 CPG NGS validation series: A resource to assess analytical sensitivity of cancer predisposition gene testing
por: Mahamdallie, Shazia, et al.
Publicado: (2018) -
The Quality Sequencing Minimum (QSM): providing comprehensive, consistent, transparent next generation sequencing data quality assurance
por: Mahamdallie, Shazia, et al.
Publicado: (2018) -
CoverView: a sequence quality evaluation tool for next generation sequencing data
por: Münz, Márton, et al.
Publicado: (2018) -
The ICR96 exon CNV validation series: a resource for orthogonal assessment of exon CNV calling in NGS data
por: Mahamdallie, Shazia, et al.
Publicado: (2017)